CollPlant Biotechnologies Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat CollPlant Biotechnologies de winst en omzet met respectievelijk 65% en 40% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 67.8% per jaar.

Belangrijke informatie

65.0%

Groei van de winst

67.8%

Groei van de winst per aandeel

Biotechs winstgroei	28.4%
Inkomstengroei	40.0%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	21 Aug 2024

Recente toekomstige groei-updates

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 22

Recent updates

We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow

Aug 20

We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow

Feb 03

Is CollPlant Biotechnologies (NASDAQ:CLGN) In A Good Position To Deliver On Growth Plans?

Nov 02

CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) Shares Lagging The Industry But So Is The Business

Sep 06

Here's Why We're Watching CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

Jul 14

Here's Why We're Not Too Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

Mar 02

Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Are In A Position To Invest In Growth

Nov 10

CollPlant Non-GAAP EPS of -$0.36, revenue of $0.07M

Aug 25

We Think CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Drive Business Growth

Jul 22

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 22

CollPlant Biotechnologies - A Cheap, Game-Changing Bio-Printing Platform Company

Aug 05

Why We Think Shareholders May Be Considering Bumping Up CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) CEO Compensation

Jul 29

The Strong Earnings Posted By CollPlant Biotechnologies (NASDAQ:CLGN) Are A Good Indication Of The Strength Of The Business

Jun 09

Winst- en omzetgroeiprognoses

NasdaqGM:CLGN - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	20	0	1	1	2
12/31/2025	13	-6	-6	-6	2
12/31/2024	2	-17	-17	-16	2
6/30/2024	1	-17	-4	-3	N/A
3/31/2024	11	-7	-3	-3	N/A
12/31/2023	11	-7	-4	-3	N/A
9/30/2023	11	-7	-5	-4	N/A
6/30/2023	11	-7	-15	-14	N/A
3/31/2023	1	-17	-15	-14	N/A
12/31/2022	0	-17	-15	-14	N/A
9/30/2022	1	-16	-14	-13	N/A
6/30/2022	1	-15	-14	-12	N/A
3/31/2022	1	-14	-14	-12	N/A
12/31/2021	16	0	1	3	N/A
9/30/2021	16	1	2	3	N/A
6/30/2021	20	5	7	8	N/A
3/31/2021	20	6	9	9	N/A
12/31/2020	6	-6	-5	-4	N/A
9/30/2020	6	-7	-5	-4	N/A
6/30/2020	3	-11	-8	-7	N/A
3/31/2020	2	-11	-8	-7	N/A
12/31/2019	2	-11	-7	-6	N/A
9/30/2019	6	-6	-2	-1	N/A
6/30/2019	6	-6	-2	-1	N/A
3/31/2019	5	-4	-2	-1	N/A
12/31/2018	5	-6	-2	-1	N/A
9/30/2018	1	-6	-7	-6	N/A
6/30/2018	1	-6	-6	-6	N/A
3/31/2018	1	-7	N/A	-5	N/A
12/31/2017	0	-6	N/A	-5	N/A
9/30/2017	0	-6	N/A	-5	N/A
6/30/2017	0	-7	N/A	-5	N/A
3/31/2017	0	-7	N/A	-5	N/A
12/31/2016	0	-7	N/A	-5	N/A
9/30/2016	0	-7	N/A	-5	N/A
6/30/2016	N/A	-7	N/A	-5	N/A
3/31/2016	N/A	-6	N/A	-5	N/A
12/31/2015	N/A	-5	N/A	-4	N/A
9/30/2015	N/A	-4	N/A	-4	N/A
6/30/2015	N/A	-4	N/A	-4	N/A
3/31/2015	N/A	-3	N/A	-3	N/A
12/31/2014	N/A	-3	N/A	-3	N/A
9/30/2014	N/A	-4	N/A	-4	N/A
6/30/2014	N/A	-4	N/A	-4	N/A
3/31/2014	N/A	-4	N/A	-4	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CLGN de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CLGN de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CLGN de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CLGN ( 40% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).

Hoge groei-inkomsten: De omzet van CLGN ( 40% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CLGN naar verwachting over 3 jaar hoog zal zijn

CollPlant Biotechnologies Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus estimates of losses per share improve by 43%

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Recent updates

CollPlant Biotechnologies Ltd. to Report Q3, 2024 Results on Nov 27, 2024

We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow

CollPlant Biotechnologies Ltd. to Report Q2, 2024 Results on Aug 20, 2024

Collplant Successfully Bio-Prints 200Cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data

CollPlant Biotechnologies Ltd. to Report Q1, 2024 Results on May 29, 2024

New minor risk - Profitability

Full year 2023 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

CollPlant Biotechnologies Ltd. to Report Fiscal Year 2023 Results on Apr 04, 2024

We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow

CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants

New minor risk - Profitability

CollPlant Biotechnologies Ltd. to Report Q3, 2023 Results on Nov 29, 2023

Is CollPlant Biotechnologies (NASDAQ:CLGN) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) Shares Lagging The Industry But So Is The Business

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

CollPlant Biotechnologies Ltd. to Report Q2, 2023 Results on Aug 24, 2023

Here's Why We're Watching CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

Consensus estimates of losses per share improve by 43%

New minor risk - Shareholder dilution

CollPlant Biotechnologies Ltd., Annual General Meeting, Jul 18, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS exceeds analyst expectations

Here's Why We're Not Too Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

CollPlant Announces Successful Pre-Clinical Results in 3D Bioprinted Regenerative Breast Implants Porcine Study and Full Achievement of Objectives

Collplant Enriches Portfolio of Rhcollagen-Based Bioinks with Launch of Collink.3Dtm 50L in Powder Form

Third quarter 2022 earnings released: US$0.40 loss per share (vs US$0.29 loss in 3Q 2021)

Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Are In A Position To Invest In Growth

Collplant Expands Rhcollagen-Based Bioink Platform with Launch of Collink.3D 90

First half 2022 earnings released: US$0.74 loss per share (vs US$0.91 profit in 1H 2021)

CollPlant Non-GAAP EPS of -$0.36, revenue of $0.07M

We Think CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Drive Business Growth

CollPlant Advances its 3D Bioprinted Regenerative Breast Implants into Porcine Study

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.10 profit in 3Q 2020)

Deputy CEO & CFO notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Investor sentiment improved over the past week

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Second quarter 2021 earnings released: US$0.30 loss per share (vs US$0.28 loss in 2Q 2020)

CollPlant Biotechnologies - A Cheap, Game-Changing Bio-Printing Platform Company

Why We Think Shareholders May Be Considering Bumping Up CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) CEO Compensation

The Strong Earnings Posted By CollPlant Biotechnologies (NASDAQ:CLGN) Are A Good Indication Of The Strength Of The Business

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven